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Abstract
ICER is a member of the CREM family of basic leucine zipper transcription factors that acts as a
dominant negative regulator of gene transcription. Four different isoforms of ICER (I, Iγ, II and
IIγ) are transcribed from the P2 promoter of the Crem gene. We previously found that each of the
ICER isoforms is induced by parathyroid hormone in osteoblasts. The goal of the present study was
to assess the function of ICER in bone by overexpressing ICER in osteoblasts of transgenic mice.
ICER I and ICER II cDNAs, each containing an N-terminal FLAG epitope tag, were cloned
downstream of a fragment containing 3.6 kb of the rat Col1a1 promoter and most of the rat Col1a1
first intron to produce pOBCol3.6-ICER I and pOBCol3.6-ICER II transgenes, respectively. Multiple
lines of mice were generated bearing the ICER I and ICER II transgenes. At 8 weeks of age, ICER
I and ICER II transgenic mice had lower body weights and decreased bone mineral density of femurs
and vertebrae. Further studies were done with ICER I transgenic mice, which had had greatly reduced
trabecular bone volume and a markedly decreased bone formation rate in femurs. Osteoblast
differentiation and osteocalcin expression were reduced in ex vivo bone marrow cultures from ICER
I transgenic mice. ICER I antagonized the activity of ATF4 at its consensus DNA binding site in the
osteocalcin promoter in vitro. Thus, transgenic mice with osteoblast-targeted overexpression of ICER
resulted in osteopenia caused primarily by reduced bone formation. We speculate that ICER regulates
the activity and/or expression of ATF/CREB factors required for normal bone formation.
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Introduction
The cAMP responsive element modulator (CREM) is a member of the CREB/ATF family of
basic leucine zipper (bZIP) transcription factors [1]. Crem encodes multiple isoforms that give
rise to both activators and inhibitors of gene expression. Crem expression is regulated at
multiple levels, including transcription from four different promoters [1–4], mRNA splicing
[4,5] and the use of alternative polyadenylation [4] and translational initiation sites [6,7].
The inducible cAMP early repressor (ICER) is transcribed from the P2 promoter of the
Crem gene [8,9]. The P2 promoter is located within the 10 kb intron between exons G and γ.
The P2 promoter contains two contiguous pairs of cAMP response element (CRE) sites termed
cAMP autoregulatory response elements (CAREs) that are strongly inducible by cAMP [10].
Four ICER isoforms (I, Iγ, II, and IIγ) can be generated by alternative splicing of the γ domain
and DNA binding domain I. The transcripts for ICER I and Iγ contain the contiguous DNA
binding domains I and II sequences. However, a stop codon at the end of the DNA binding
domain I prevents translation of DNA binding domain II. Due to alternative splicing, the
transcripts for ICER II and IIγ contain only DNA binding domain II. DNA binding domains I
and II are very similar and thus, all ICER proteins, which consist almost exclusively of the
bZip domain of CREM, are thought to have similar activity as transcriptional repressors [1].
ICER was first discovered in pineal gland and plays a role in the regulation of circadian rhythms
[11]. ICER was subsequently shown to regulate a variety of other cellular functions including
interleukin-2 [12,13] and interleukin-4 [14] production in T cells, cyclin A expression and cell
proliferation in AtT20 cells [15] and Fas ligand expression in T and natural killer lymphocytes
[16]. Rat and human prostate tumor cells engineered to overexpress ICER are unable to form
tumors in nude mice [17,18]. The sustained induction of ICER leads to cardiac myocyte
apoptosis [19]. An important aspect of ICER biology is its ability to repress its own production.
ICER homodimers inhibit transactivation of the P2 promoter by binding to the CAREs [1,
20]. This represents an autoregulatory feedback loop that allows the resetting of ICER-inhibited
gene expression. Thus, ICER may be responsible for shaping the transient induction of gene
expression in response to cAMP.
We previously reported that each of the four ICER isoforms is rapidly and transiently induced
by PTH in osteoblasts via the cAMP-PKA signaling pathway [21,22]. Moreover, we showed
that induction of a transfected Pghs2 promoter-reporter construct with forskolin, a direct
adenylase cyclase stimulator, is inhibited by transfection of an ICER IIγ expression construct
in MC3T3-E1 cells. This led us to speculate that ICER induction in osteoblasts might represent
a mechanism for regulating gene expression in response to PTH and other agonists that increase
cAMP levels. To gain insight into the actions of ICER in vivo, we developed transgenic mice
that overexpress ICER I and ICER II broadly in cells of the osteoblast lineage. Osteoblast-
targeted ICER transgenic mice showed reduced body size, trabecular bone volume and bone
formation. Bone marrow cultures from ICER transgenic mice displayed reduced osteoblast
differentiation.
Materials and Methods
Animals
All animal care procedures were reviewed and approved by the University of Connecticut
Health Center Animal Care Committee. To produce ICER transgenic mice, FLAG-ICER I and
FLAG-ICER II cDNAs were amplified by PCR from pCR3.1-F-ICER with an Xba I-built-in
5’ primer and a 3’ primer corresponding to the 3’ end of ICER I. The PCR products were cloned
directly to a pCR2.1 vector (Invitrogen Company, Carlsbad, CA). After verifying the
orientation and the sequence of the inserts, the Xba I fragment was released and cloned into a
Chandhoke et al. Page 2
Bone. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
ClaPa polylinker, which is flanked by Cla sites and contains a the bovine growth hormone
polyadenylation (bGH poly A) sequence [23]. The FLAG-ICER-bGH poly A cassette was
released by digestion with Cla1 and cloned into pBC-SK+, which contains the rat Col1a1 gene
fragment from –3518 to +1594 bp including part of the first exon in which the AUG initiator
has been mutated and most of the first intron [23]. This step produced the pOBCol3.6-ICER
transgenes (Figure 1). The downstream Xho I site of the pOBCol3.6-ICER transgenes were
mutated to an Sst II site with a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA). Sst II fragments of pOBCol3.6-ICER I and II were gel purified and microinjected into
CD-1 embryos to generate transgenic lines. The transgenes were detected as a 700 nt product
by PCR of tail DNA using primers corresponding to the rat Col1a1 first intron (5’-
ACCCTCCTCCATTTTAGCC) and the FLAG sequence (5’-CATCGTCGTCCTTGTAGTC)
with denaturation at 94 C for 30 sec, annealing at 65 C for 30 sec and extension at 72 C for 2
min for 32 cycles [24]. To generate experimental mice, mating units typically consisted of wild
type females and hemizygous transgenic males.
In some experiments, pOBCol3.6-ICER I mice (line 284) were bred with mice containing a
green fluorescent protein (GFP) transgene driven by a 2.3-kb fragment of the rat Col1a1
promoter and part of the first Col1a1 intron (pOBCol2.3-GFP) (kindly provided by Dr. David
Rowe), which is a real time, fluorescent marker of mature osteoblasts [25]. Homozygous
pOBCol2.3-GFP mice were bred with hemizygous pOBCol3.6-ICER I mice. This yielded
progeny that were all hemizygous for the pOBCol2.3-GFP transgene and either wild type or
hemizygous for the pOBCol3.6-ICER I transgene.
Immunostaining
Primary calvarial osteoblasts from 7-day-old wild type and transgenic mice were prepared as
previously described [26]. Immunostaining for the FLAG-tagged ICER I transgene was
performed as previously described with some modifications [24]. Primary neonatal calvarial
osteoblasts were plated in αMEM medium with 10% heat-inactivated fetal calf serum at 8600
cells/well in a 4-well chamber slide. Cells were grown to 60–80% confluence. The medium
was removed and cells were washed, fixed and stained using the M2 monoclonal primary
antibody that recognizes the FLAG epitope (Sigma-Aldrich, St. Louis, MO), a biotinylated
secondary anti-mouse IgG (1:200) and horseradish perioxidase streptavidin (1:100).
Transient transfection
MC3T3-E1 and HEK293 cells were transfected with the expression constructs pCR3.1-ICER
I and pCMV-ATF4 and a promoter-reporter luciferase construct: one containing 4 tandem
OSE1 sites driving luciferase (p4OSE1-luc) and one containing 6 tandem OSE2 sites driving
luciferase (p6OSE2-luc) [27]. Transfections were performed using the Lipofectamine
PLUSTM kit (Invitrogen). The amount of DNA in each transfection reaction was equalized
using empty expression vectors, (pCR3.1-MT or pCMV-MT). Luciferase constructs were
added at 0.25 μg/reaction for all reactions. Luciferase activity was measured 24 hours after
transfection using a Promega Assay kit. Cells were lysed with 1X Cell Culture Lysis Reagent
and supernatants harvested by centrifugation. Ten μl of each lysate was analyzed using a
Berthold LB 9501/16 luminometer (Wallac, Inc.) and normalized to protein content [28].
Bone mineral density and morphometry
Femurs and the third lumbar vertebra (L3) were dissected from 8-week-old mice and stored in
70% ethanol. Bone mineral density (BMD) of the femurs and L3 vertebrae were determined
by dual energy X-ray absorptiometry (DEXA) using PIXImus mouse densitometer (Lunar
Corporation, Madison, WI). Cortical and trabecular morphometry of femurs was quantified at
mid-diaphysis and within the distal metaphysis, respectively, using conebeam X-ray computed
microtomography (microCT) using a μCT40 instrument (Scanco Medical AG, Bassersdorf,
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Switzerland) as previously described [26]. Segmentation of bone from marrow and soft tissue
was performed in conjunction with a constrained Gaussian filter (to reduce noise) at density
thresholds of 712 mg/cm3 and 474 mg/cm3 for cortical and trabecular compartments,
respectively. Volumetric regions for trabecular analysis were selected within the endosteal
borders to include the secondary spongiosa of femoral metaphyses located 960 μm from the
growth plate and extending 1 mm proximally. Trabecular morphometry was assessed by
measuring bone volume fraction (BV/TV), trabecular thickness (TbTh) and trabecular number
(TbN). Cortical morphometry was quantified and averaged for 50 serial cross-sections (600
μm) extending distally from the diaphyseal midpoint between proximal and distal growth
plates. Cortical measurements included average cortical thickness, cross-sectional area of
cortical bone, and sub-periosteal cross-sectional area (bone plus marrow, an index of cross-
sectional dimensions).
Bone histomorphometry
Seven-week-old wild type and ICER I (line 284) female mice were injected intraperitoneally
with calcein (10 mg/kg body weight) and 7 days later with xylenol orange (90 mg/kg body
weight). Mice were euthanized 2 days after the second injection. Femurs were dissected free
of tissue and fixed in 4% paraformaldehyde. The undecalcified femurs were dehydrated in
increasing concentrations of ethanol, cleared in xylene, and embedded in methyl methacrylate.
Five-micron-thick longitudinal serial sections were taken from the middle of the femur as
defined by the location of a central vein. Measurements were made blinded as to the treatment
group using an OsteoMeasure computerized image analysis system (OsteoMetrics, Inc.
Atlanta, GA) interfaced with an Optiphot Nikon microscope (Nikon Inc., Melville, NY) at a
magnification of 20x. All measurements were confined to an area of the secondary spongiosa
between 400 and 2000 microns distal to the growth plate-metaphyseal junction of the distal
femur. We used terminology and units recommended by the Histomorphometry Nomenclature
Committee of the American Society for Bone and Mineral Research [29].
Osteoblast differentiation
Bone marrow was flushed from the long bones of 8-week-old male mice into αMEM and sieved
through a 40-μm cell strainer (Becton Dickinson, Franklin Lakes, NJ). Cells were plated at 1.7
x 106/ml in 35 mm wells in αMEM supplemented with 10% non-heat-inactivated FCS, 100 U/
ml penicillin and 50 μg/ml streptomycin. On day 3, half of the medium was removed and
replenished with fresh medium. On day 7, the medium was completely replenished and cells
were cultured in osteogenic differentiation medium containing α-MEM with 10% non heat-
inactivated FCS, 100 U/ml penicillin, 50 μg/ml streptomycin and 8 mM β-glycerophosphate
and 50 μg/ml ascorbic acid. Medium was changed every 2 days until day 28.
Cultures were analyzed for alkaline phosphatase and mineral staining on days 14, 21 and 28
while RNA was isolated on days 14 and 21 for gene expression studies. Alkaline phosphatase
staining was performed using a commercial kit (Sigma Diagnostics, Inc., St. Louis, MO). To
assess mineralization, plates stained with alkaline phosphatase were further stained with von
Kossa reagent. Plates were rinsed briefly with water and treated with LiCO3 for 20 min. After
a brief rinse with water, cells were covered with 5% AgNO3 for 1 h under bright light. To
assess GFP fluorescence, cultures were analyzed using a Fluorimager SI instrument (Molecular
Dynamics, Sunnyvale, CA). A 515nm long pass emission filter was with a photomultiplier
tube voltage (PMT) of 800 was utilized for optimal detection. Digital images of excitation
spectra were processed using ImageQuaNT software (Molecular Dynamics). To assess gene
expression, total RNA was extracted using TRIzol Reagent (GibcoBRL) as previously
described [30]. RNA was redissolved in GTC buffer and precipitated in isopropanol. RNA was
washed in 80% ethanol, dissolved in diethylpyrocarbonate (DEPC) water and stored at -80 C
until use. For Northern blot analysis, total RNA was denatured and fractionated on an agarose
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gel and transferred to a nitrocellulose membrane by capillary transfer. Transferred RNA was
hybridized to the membrane, which was then exposed to existing 32P-labelled cDNA probes
for Col1a1, bone sialoprotein (BSP), osteocalcin (OC) and β-actin. Signals were quantified as
described previously [30].
Osteoclast formation
Marrow was flushed from the long bones of 8-week-old female with □MEM and filtered with
a 40-μm cell strainer (Becton Dickinson, Franklin Lakes, NJ). The harvested marrow cells
were plated at 25,000/well in a 48-well dishes in αMEM supplemented with 10% heat-
inactivated FCS and 30 μg/ml each of M-CSF and RANK ligand (both from R&D Systems,
Inc., Minneapolis, MN). The culture medium was changed on day 3. Tartrate resistant acid
phosphatase (TRAP) staining was performed on days 3, 4 and 5 using a leukocyte acid
phosphatase staining kit (Sigma Diagnostics Inc., St. Louis, MO) according to the
manufacturer’s protocol. TRAP-positive cells containing 3 or more nuclei per cell were
counted under a microscope.
Serum markers
Serum osteocalcin was measured by radioimmunoassay using a goat anti-mouse osteocalcin
antibody as previously described [31]. Serum C-terminal telopeptide of α1(I) collagen (CTX)
was measured by an enzyme-linked immunosorbent assay (ELISA) using a RatLaps kit (Nordic
Bioscience Diagnostics, A/S).
Results
Transgenic lines overexpressing pOBCol3.6-ICER I and pOBCol3.6-ICER II in osteoblasts
were generated by embryo microinjection. Transgene mRNA was highly expressed in calvaria,
femur and vertebra, with lower expression in skin and tendon and virtually no expression in
other tissues (not shown). Transgene mRNA expression varied among the lines. Of the ICER
I transgenic lines, expression was highest in lines 284 and 285, which were chosen for further
examination (Figure 1B). Of the ICER II lines, expression was highest in line 251, but this line
was lost. Therefore, line 214 was chosen for examination. Primary calvarial osteoblasts from
wild type and ICER I mice (line 284) were cultured and stained for FLAG-tagged ICER protein
using the M2 antibody, which recognizes the FLAG epitope. Staining was not seen in wild
type cells (Figure 1C), while strong immunostaining was seen in most transgenic cells (Figure
1D). These data indicated that the ICER transgenes were highly expressed in osteoblasts at
both the mRNA and protein level.
Six- and eight-week-old line 284 mice (ICER I) had reduced body weight compared to wild-
type littermates (Figure 2A). Lines 285 and 214 (ICER I and ICER II, respectively), which
expressed lower levels of the ICER transgene, also showed a weight difference, although not
as marked as line 284 (Figure 2A). The BMD of dissected femurs was greatly reduced in males
and females mice of line 284. (Figure 2B). There was also a reduction in BMD in femurs of
lines 285 and 214, although females were more affected than males (Figure 2B and C). The
BMD differences for males of lines 285 and 214 did not reach statistical significance.
Adult line 284 mice (ICER I) had a scarcity of trabecular bone in the primary spongiosa of
distal femurs compared to wild type littermates (Figure 3A and B). Histomorphometric analysis
of line 284 femurs showed a significant reduction in trabecular bone volume fraction (BV/TV
%) (Figure 3C). The mineral apposition rate (MAR) and bone formation rate per bone surface
(BFR/BS) were profoundly decreased in transgenic mice (Figure 3C). Neonatal calvaria from
ICER I mice (line 284) showed a marked reduction in expression of osteocalcin mRNA, a
marker of mature osteoblasts; however, Col1a1 was not greatly affected while bone
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sialoprotein (BSP) was increased (Figure 3D). Serum osteocalcin, a marker for bone formation
was reduced in sera of line 284 mice (ICER I) compared to wild type littermates (Figure 3C).
Together, these data indicated that bone formation was reduced in ICER I mice.
TRAP staining was seen in the primary spongiosa of both wild type and line 284 mice (ICER
I, Figures 3A and B). Osteoclast number per bone surface was not significantly altered in
transgenic femurs (not shown), although this may have been due to lack of a sufficient amount
of trabecular template for an adequate assessment. Serum CTX was unchanged in line 284
(ICER I, Figure 3E). These data indicate that osteoclast formation and bone resorption were
not greatly affected in ICER I mice.
Bone morphometry of line 284 mice (ICER I) was evaluated by microCT (Figure 4). Three-
dimensional images showed dramatic reduction in the trabecular bone compartment in line 284
(Figure 4B) compared to wild type femurs (Figure 4C). Trabecular bone volume, number and
thickness were greatly reduced in line 284 femurs Figure 4C). Cortical bone morphometry at
the mid-diaphyseal region of femurs was affected in line 284 mice (Figure 4D and E). The
subperiosteal area of male line 284 femurs was significantly reduced, although this parameter
was not altered in female line 284 femurs (Figure 4F). Cortical bone area and thickness were
decreased in both male and female line 284 femurs (Figure 4F).
To determine the effect of the ICER transgene on osteoblast differentiation, bone marrow
cultures were established from ICER I (line 284) and wild type mice that were bred to
incorporate a pOBCol2.3-GFP transgene, which is a real time, fluorescent marker of mature
osteoblasts [25]. Homozygous pOBCol2.3-GFP mice were bred with hemizygous pOBCol3.6-
ICER I transgenic mice. This yielded progeny that were all hemizygous for the pOBCol2.3-
GFP transgene and either wild type or hemizygous for the pOBCol3.6-ICER I transgene (line
284). In bone marrow stromal cultures, von Kossa staining was greatly reduced in line 284
(ICER I) cultures at day 21 (Figure 5A). GFP fluorescence at day 21 (Figure 5B), and BSP and
OC mRNA levels at days 14 and 21 (Figure 5C), were reduced in line 284 (ICER I) cultures.
Bone marrow cells from 8-week-old line 284 (ICER I) and wild type female mice were treated
with M-CSF and RANKL to induce osteoclast differentiation. The number of TRAP-positive
multinucleated cells in transgenic cultures was increased by 2-fold on day 3 of culture but was
not changed at days 4 and 5 (Figure 5D). Taken together, the ex vivo cellular differentiation
studies indicated that the ICER I transgene primarily affected osteoblast differentiation.
ICER I (line 284) mice showed a dramatic loss of femoral trabecular bone in vivo and a marked
reduction in osteocalcin expression but Col1a1 expression was not dramatically altered. This
phenotype was reminiscent of ATF4 knockout mice and raised the possibility that ICER
antagonizes the activity of ATF4 in transgenic mice [32]. We therefore examined ICER I
function at the OSE1 site that binds ATF4 in the mouse osteocalcin promoter. We utilized an
OSE1 construct, containing four OSE1 sequences in tandem driving luciferase expression
(p4OSE1-Luc). ATF4 induced p4OSE1-Luc activity (Figure 6A). However, when cells were
co-transfected with increasing amounts of an ICER I expression plasmid (pCR3.1-ICER I), the
induction of the OSE1 construct was potently repressed. Thus, ICER I repressed ATF4 activity
in at the OSE1 site. To determine the specificity of this transcriptional repression, we examined
the effect of ICER I at the OSE2 site of the osteocalcin promoter. This site was chosen because
Runx2 is the primary transcriptional regulator of osteocalcin expression and because it
cooperates with ATF4 at the OSE2 site. Runx2 induced a multimerized OSE2 construct driving
luciferase (p6OSE2-Luc) in HEK293 cells (Figure 6B). At low levels (0.1 μg), ICER I appeared
to augment OSE2 activity in response to Runx2. As the concentration of ICER I plasmid
increased, p6OSE2-luc activity decreased, although not below the level induced by Runx2
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alone. This was in sharp contrast to the repression of ATF4 activity by ICER I at the OSE1
site.
Discussion
We previously showed that all ICER isoforms are induced by PTH in cultured osteoblasts and
in bone in vivo [21]. To explore the effects of ICER in vivo, we generated transgenic mice in
which a 3.6-kb fragment of the rat Col1a1 promoter and most of the first intron of Col1a1
directed ICER I and II expression to osteoblasts. This promoter fragment has been well
characterized with respect to its temporal and spatial pattern of expression in mouse tissues
[25,33,34]. We found that the bone mineral density was reduced in transgenic femurs. This
change was seen in two independent lines of ICER I mice with varying levels of transgene
expression and one line of ICER II mice. In ICER I transgenic lines, the strength of the
phenotype was associated with the level of transgene expression indicating that the bone
phenotype was independent of the transgene integration site. The phenotypes of the ICER I
and ICER II transgenic lines were similar. Due to alternative splicing of the CREM gene, ICER
I and ICER II proteins differ in their DNA binding domain. The alternative DNA binding
domains I and II encoded by the Crem gene are very similar. As a result, the dominant negative
function of the ICER I and ICER II proteins are thought to be equivalent, although this has not
been studied systematically. Each of the four ICER proteins repressed the inhibin α-subunit
promoter in transfected mouse granulosa cells [35] and the Fas ligand promoter in transfected
T lymphocytes [16]. In primary cultures of human endometrial stromal cells, ICER I and ICER
II equally repressed PKA-induced expression of transfected prolactin promoter-reporter
constructs [7].
Transgenic distal femurs of ICER I mice (line 284) had a striking paucity of trabecular bone.
Osteoblast differentiation was markedly impaired in bone marrow cultures and serum
osteocalcin levels were reduced in these animals. By contrast, osteoclast number per bone
surface in distal femurs and serum CTX were unchanged, and osteoclast formation was only
transiently increased in bone marrow cultures from line 284. Taken together, these data suggest
that the decrease in bone mass in ICER I mice was largely due to decreased bone formation.
Using a similar in vivo strategy, tissue selective promoters have been used to generate
transgenic mice with ICER expression targeted to pancreatic β-cells [36] and thymocytes
[37].
bZIP factors are grouped into thirteen families based on their dimerization properties [38].
ICER is classified as a member of the CREB/CREM/ATF1 family within the broader ATF/
CREB superfamily. Members of the CREB/CREM/ATF1 family form both homo- and
heterodimers within the family that bind to palindromic CRE sites [38]. ICER consists almost
exclusively of the bZIP domain of CREM and is devoid of transactivation domains rendering
it a potential dominant negative transcription factor. ICER homodimers can function as
transcriptional repressors by binding with high affinity to CRE sites [1] precluding the
recruitment of other factors required for necessary for transcriptional initiation [39]. For
example, ICER prevents α-inhibin transcription by in ovarian granulosa cells by preventing
CREB binding to a CRE site [35]. Alternatively, ICER can form inactive heterodimers with
transcription factors such as CREB and CREM [3] and NFAT [13,14].
Of paramount interest are the observations that Atf4 knockout mice have low bone mass
characterized by reduced trabecular bone volume and that Atf4 knockout osteoblasts show
impaired differentiation ex vivo [32,40]. ATF4 induces osteocalcin expression and a distinct
binding site for ATF4 was discovered as OSE1, a cis-acting element in the osteocalcin promoter
[32]. In addition, although Col1a1 mRNA expression is maintained in osteoblasts from Atf4
knockout mice, type I collagen protein synthesis is greatly decreased, suggesting a role for
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ATF4 in post-translational modification of type I collagen. ATF4 and Runx2 cooperate in the
activation of the osteocalcin gene [27]. Due to noteworthy parallels in the phenotype we have
observed in ICER I transgenic mice, specifically with regard to dramatic effects on the
trabecular bone compartment and osteocalcin expression in ex vivo osteoblast cultures as well
as in vivo expression (data not shown), we believe it is possible that ICER interacts with ATF4
to disrupt its ability to activate genes necessary for physiologic bone remodeling. To address
the role of ICER in modulating ATF4 at its OSE1 site, we utilized a promoter-reporter construct
using a multimerized OSE1 promoter driving luciferase (p4OSE1-Luc). Consistent with
previous studies [27,32], ATF4 potently activated the OSE1 construct driving high expression
of the luciferase reporter in both MC3T3-E1 (clone MC-4) and HEK293 cells. However, when
cells were co-transfected with both ATF4 and ICER, there was a profound suppression of
ATF4-mediated activation to baseline, showing that ICER dramatically disrupted ATF4
function at its OSE1 binding site. However, ICER did not repress Runx2 activity at the OSE2
site, showing specificity of the ICER effect. In preliminary studies, we found that ICER does
not bind strongly if at all to the OSE1 site; rather it may decrease the binding of ATF4 to the
OSE1 site (data not shown). Further studies will be necessary to support these results. Recently,
the factor inhibiting ATF4-mediated transcription (FIAT) was identified in osteoblasts [41].
FIAT, a bZIP factor inhibits ATF4-mediated transcription by forming an inactive heterodimer
with ATF4. Transgenic expression of FIAT with a 2.3-kb fragment of the mouse Col1a1
promoter resulted in greatly decreased trabecular bone volume and osteocalcin expression
[41]. This model has interesting phenotypic similarities with ICER transgenic mice, thus
strengthening our hypothesis that ATF4 is a target of ICER.
Although we hypothesize that ATF4 is a target of ICER, it is very likely that ICER interacts
with and regulates the activity of other transcription factors in osteoblasts. Components of the
dimeric AP-1 complex, which include FOS and JUN proteins, may also be direct targets of
ICER. Although the c-FOS is best known for its role in osteoclast formation [42,43], the
anabolic effect of PTH on bone acquisition is in part dependent on the c-Fos gene [44]. Fra-1
and deltaFosB, a splice variant of FosB, are stimulators of osteoblast differentiation and
function. Mice with a conditional knockout of Fra-1 develop osteopenia [45], while Fra-1
[46,47] and deltaFosB [48,49] transgenic mice display osteosclerosis. C/EBPβ is another
intriguing candidate for interacting with ICER since C/EBPβ synergizes with Runx2 to induce
osteocalcin gene expression during osteoblast differentiation [50,51]. Moreover, C/EBP
factors can heterodimerize with selected ATF/CREB proteins [52]. Therefore, it is conceivable
that transgenic ICER protein could have prevented C/EBPβ from interacting with Runx2, thus
blocking osteoblast differentiation. ICER transgenic mice have phenotypic similarities to mice
with an osteoblast-targeted C/EBPβ p20 transgene including a marked decrease in femoral
trabecular bone volume. Since p20 can act as a dominant negative molecule, ICER and p20
transgenes may converge on a similar pathway [53]. In our model, ICER is expressed
constitutively at supraphysiological levels. This raises the possibility that transgenic ICER may
interact with transcription factors that are not normally engaged by physiological levels of
ICER.
The low bone mass in ICER transgenic mice was due largely by an inhibition of bone formation.
Interestingly, we have shown that Crem knockout mice, which are devoid of ICER and other
CREM isoforms, have slightly increased bone mass, consistent with the loss of a repressor
such as ICER [54]. The ICER transgenic models raise the possibility that ICER is a mechanism
to regulate the strength and timing of the activity of ATF/CREB factors that participate in
osteoblast differentiation and function (i.e. a fine tuning mechanism). Our past work has shown
that ICER is induced by PTH and other agonists that increase cAMP [21,22]. We reason that
by antagonizing the activity of multiple factors such as CREB and ATF4, ICER modulates
pathway that control bone formation. Downstream targets of ICER may include hormones such
as insulin-like growth factor-I (IGF-I), which is known to be regulated by cAMP [55] and
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mediates in part the anabolic effects of PTH on bone mass accrual [56] and the Wnt pathway,
which is stimulated by PTH-induced cAMP [57]. Further studies in our laboratory are designed
to identify the molecular targets of ICER that regulate bone formation.
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Figure 1.
Generation of ICER transgenic mice. (A) The pOBCol3.6-ICER transgenes consist of the ICER
I or II cDNA, a 3.6-kb fragment of the rat Col1a1 gene including 3.5 kb of promoter and 115
bp of first exon, 1.6 kb of the rat Col1a1 first intron and the bovine growth hormone
polyadenylation site. (B) Northern blot analysis of ICER mRNA in long bones expressing
either the ICER I or ICER II transgenes. (C, D) Immunostaining of primary calvarial osteoblast
cultures established from wild type (WT) and ICER I (line 284) transgenic (TG) mice. Primary
cultures were prepared from neonatal calvaria as described in Materials and Methods. Cultures
were grown almost to confluence and stained with the M2 antibody that recognizes the FLAG
epitope in the ICER I transgene.
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Figure 2.
Phenotypic analysis of ICER transgenic (TG) mice. (A) Body weights were measured at 3, 6
and 8 weeks of age. Each value represents the mean ± SD of 7–22 mice for line 284 (ICER I),
2–5 mice for line 285 (ICER I) and 8–21 mice for line 214 (ICER II) mice except for the line
285 TG male group at 3 weeks, which is one mouse. Body weights for TG mice were
significantly different (p<0.05) from the respective sex-matched wild type (WT) groups for all
age points for line 284 and for the 6- and 8-week age points for line 214. (B) BMD
measurements assessed by DEXA in 6- to 8-week-old mice in these lines. Each value is the
mean ± SEM for 5–13 mice. *Different from the sex-matched WT group, p<0.01.
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Figure 3.
In vivo analyses of wild type and ICER I (line 284) transgenic mice. Hematoxylin and eosion
staining of longitudinal sections of a wild type (A) and transgenic (B) femur counterstained
with TRAP at 20X magnification. (C) Histomorphometric and serum osteocalcin
measurements. Bone volume normalized to total volume (BV/TV) was measured by static
histomorphometric analysis. Each value represents mean ± SEM for 14 wild type (WT) and 4
transgenic (TG) femurs. Mineral apposition rate (MAR) and bone formation rate normalized
to bone surface (BFR/BS) were determined by dynamic histomorphometric analysis of double-
labeled surface of active bone formation. Each value represents the mean ± SEM of 10 WT
and 5 TG mice. Serum osteocalcin protein level measured by ELISA was utilized as a
biochemical marker of bone formation from sera of 6- to 8-week-old mice. Each value
represents the mean ± SEM of 8 WT and 9 TG mice. Values for males and females were pooled.
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*Different from WT, p<0.01. (D) Northern blot analysis of a1(I) collagen (Col1a1), bone
sialoprotein (BSP) and osteocalcin (OC) mRNA levels in calvaria of neonatal WT and ICER
I (line 284) TG mice. EtBr, ethdidium bromide. (E) Serum levels of the C-terminal telopeptide
of α1(I) collagen (CTX) links in WT and TG mice. Each value is the mean ± SEM of 9 WT
and 9 TG mice. Values for males and females were pooled.
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Figure 4.
Microcomputed tomographic (MicroCT) analysis of femurs from 7.5-week-old ICER I mice
(line 284). Three-dimensional images corresponding to the trabecular bone compartment of
(A) wild type (WT) and (B) transgenic (TG) femurs. (C) BV/TV, trabecular number (Tb.N)
and trabecular thickness (Tb.Th) measurements in male and female WT and TG mice. Cross-
sectional images displaying the cortical bone integrity of WT (D) and TG (E) femurs. (F)
Cortical bone measurements extrapolated from MicroCT analysis including cross-sectional
area, cortical bone area and cortical thickness in male and female WT and TG mice. Each value
is the mean ± SD for 12 WT males, 8 TG males, 6 WT females and 6 TG females.
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Figure 5.
Ex vivo culture of bone cells from ICER I mice (line 284). (A) Bone marrow stromal cells
from 6- to 8-week-old wild type (WT) and transgenic (TG) mice were cultured in osteogenic
medium until day 21 and stained with alkaline phosphatase and von Kossa stain. Three replicate
wells are shown. (B) Heterozygous pOBCol3.6-ICER I mice (line 284) were bred homozygous
pOBCol2.3-GFP mice. All progeny were heterozygous for the pOBCol2.3-GFP transgene and
either wild type (WT) or hemizygous for the pOBCol3.6-ICER I (line 284) transgene (TG).
Bone marrow stromal cultures were prepared from WT and TG mice and examined for GFP
fluorescence with a fluorimager. GFP fluorescence is shown in WT and TG cultures at day 21.
Three replicate wells are shown. (C) Analysis of mRNA markers of osteoblast differentiation.
Bone sialoprotein (BSP) and osteocalcin (OC) expression was analyzed by Northern blot
analysis of cultures at day 14 and 21 in WT and TG mice. Ethidium bromide (EtBr) staining
was used as a loading control. These data are representative of three experiments. (D)
Osteoclastogenesis was assessed in ex vivo bone marrow cells cultured with M-CSF (30 ng/
ml) and RANKL (30 ng/ml) as described. For each day of culture, osteoclast number (OCL)
in TG cultures was normalized to WT values. Each value represents the mean ± SEM of three
experiments. *Significant effect of the transgene, p<0.05.
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Figure 6.
(A) ICER dose response to ATF4 at the OSE1 site. MC3T3-E1 cells (MC-4 clone) were
transfected with pCMV-ATF4 and 4OSE1-Luc and co-transfected with increasing
concentrations of pCR3.1-ICER I. Luciferase activity was normalized to total protein using
the BCA assay. (B) ICER does not modulate Runx2 activity at the OSE2 site. Increasing
concentrations of ICER expression plasmid were co-transfected with Runx2 vector and
6OSE2-luc in HEK293 cells. Luciferase activity was normalized to total protein.
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